Wright Brings New Biologic To U.S. Ortho Space With Augment Approval
This article was originally published in The Gray Sheet
Executive Summary
The Augment biologic-based device was approved for use in ankle and hindfoot fusions after overcoming multiple regulatory challenges.
You may also be interested in...
Cervical Spine Bone Graft Gains FDA Go-Ahead
Cerapedics' i-Factor peptide-enhanced bone graft will be used to treat degenerative cervical disc disease, the first bone graft product PMA-approved for that indication, the company says.
Wright Medical Augments Ortho Extremities Biz With BioMimetic Purchase
Firm expects to gain PMA approval in 2013 for BioMimetic’s Augment bone graft as a replacement for autologous bone graft in foot and ankle fusion procedures. Deal includes $190 million down, and up to $190 million more in milestone payments.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.